26
|
Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Hosaka M, Kawai A, Nakatani F, Kobayashi E, Nishida Y, Okamoto T, Matsunobu T, Iwamoto Y, Fukuda H, Ozaki T. A randomized phase III study of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group study JCOG1610. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Noda S, Yonemori K, Shirakawa N, Okuma H, Shimizu T, Hirakawa A, Shibata T, Sukigara T, Okita N, Kawai A, Yamamoto N, Nakamura K, Mano H, Nishida T, Fujiwara Y. MASTER KEY project: A basket/umbrella trial for rare cancers in Japan. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Ito T, Kenmochi T, Aida N, Kurihara K, Kawai A, Ito T. Effectiveness of Preceding Solo Kidney Transplantation for Type 1 Diabetes With End-Stage Renal Failure. Transplant Proc 2018; 50:3249-3254. [PMID: 30577193 DOI: 10.1016/j.transproceed.2018.06.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Accepted: 06/19/2018] [Indexed: 11/18/2022]
Abstract
Preceding solo kidney transplantation for type 1 diabetes with end-stage renal failure is controversial because of less pancreatic graft survival in pancreas transplantation after kidney transplantation (PAK) than in simultaneous pancreas and kidney transplantation (SPK). METHODS To study the effectiveness of preceding solo kidney transplantation for type 1 diabetes with end-stage renal failure, comparative retrospective analysis was performed between SPK (n = 232) and PAK (n = 39) that were performed until December 2016. RESULTS At 1, 3, and 5 years, pancreatic graft survival in SPK was 87.5%, 86.4%, and 82.8%, respectively, and 87.1%, 65.0%, and 49.1%, respectively, in PAK, which showed lesser long-term graft survival than SPK. Because 10 cases out of 16 (62.5%) failed into pancreatic graft loss with rejection in PAK, which was about 3 times more than in SPK, control of rejection is very important; rejection episodes were decreased by rabbit antithymocyte globulin induction resulting in improved graft survival. Five-year patient survival was 88.0% in SPK and 96.6% in PAK. CONCLUSION Considering patient survival, preceding solo kidney transplantation for type 1 diabetes with end-stage renal failure should be performed if a donor is available.
Collapse
|
29
|
Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. Ann Oncol 2018; 28:1230-1242. [PMID: 28184416 PMCID: PMC5452071 DOI: 10.1093/annonc/mdx054] [Citation(s) in RCA: 138] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this group were published, covering the management of primary and metastatic chordomas. Additional evidence and further discussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF convened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recommendations of the first position paper.
Collapse
|
30
|
Kobayashi E, Kawai A, Yonemori K, Tamura K. Eribulin mesylate in patients with soft-tissue sarcoma other than L-sarcoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx675.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Kim R, Kawai A, Wakisaka M, Funaoka Y, Yasuda N, Ohtani S, Ito M, Arihiro K. A role for immune response in the response to neoadjuvant chemotherapy for breast cancer patients. Breast 2017. [DOI: 10.1016/s0960-9776(17)30260-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Chen TW, Pang A, Puhaindran M, Maw M, Loong H, Sriuranpong V, Chang CC, Teo S, Mingmalairak S, Hirose T, Endo M, Kawai A, Farid M, Tan S, Goh W, Quek R, Chan J, Leung A, Ngan R. 502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Chen TW, Pang A, Puhaindran M, Maw M, Loong H, Sriuranpong V, Chang CC, Teo S, Mingmalairak S, Hirose T, Endo M, Kawai A, Farid M, Tan S, Goh W, Quek R, Chan J, Leung A, Ngan R. 502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00660-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
34
|
Kobayashi E, Kawai A, Chuman H. 509P Desmoid-type fibromatosis with a remarkable response to pazopanib treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Quek R, Loong H, Sriuranpong V, Farid M, Tan S, Goh W, Mingmalairak S, Chen TW, Chang CC, Pang A, Teo S, Puhaindran M, Maw M, Ngan R, Leung A, Chan J, Hirose T, Endo M, Kawai A. 501O_PR Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Nishikawa T, Yonemori K, Kitano A, Shimoi T, Noguchi E, Yunokawa M, Shimizu C, Fujiwara Y, Yoshida A, Kobayashi E, Nakatani F, Kawai A, Chuman H, Koyama T, Shimomura A, Kitano S, Shimizu T, Fujiwara Y, Yamamoto N, Tamura K. 511P Retrospective study of sarcoma in practical and developmental therapeutics in Japan. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00669-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
37
|
Endo M, Sugawara M, Yoshida A, Kobayashi E, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Tamura K, Toki S, Hirose T, Uehara T, Mori T, Shimizu K, Tanzawa Y, Nakatani F, Chuman H, Kawai A. 503O_PR CIC-rearranged sarcoma and BCOR-CCNB3 sarcoma: Clinical characteristics and treatment results of the newly-established “Ewing sarcoma-like” small round cell sarcomas. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00661-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
38
|
Endo M, Sugawara M, Yoshida A, Kobayashi E, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Tamura K, Toki S, Hirose T, Uehara T, Mori T, Shimizu K, Tanzawa Y, Nakatani F, Chuman H, Kawai A. 503O_PR CIC-rearranged sarcoma and BCOR-CCNB3 sarcoma: Clinical characteristics and treatment results of the newly-established “Ewing sarcoma-like” small round cell sarcomas. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Noguchi E, Yonemori K, Shimoi T, Yunokawa M, Okuma H, Kawachi A, Kitano A, Nishikawa T, Shimomura A, Shimizu C, Takiguchi Y, Kawai A, Fujiwara Y, Tamura K. 154P Clinical trial designs for the approval of rare cancer drugs in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Kobayashi E, Kawai A, Chuman H. 509P Desmoid-type fibromatosis with a remarkable response to pazopanib treatment. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00667-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
41
|
Quek R, Loong H, Sriuranpong V, Farid M, Tan S, Goh W, Mingmalairak S, Chen TW, Chang CC, Pang A, Teo S, Puhaindran M, Maw M, Ngan R, Leung A, Chan J, Hirose T, Endo M, Kawai A. 501O_PR Epidemiology, real world treatment and outcomes of 423 patients (pts) with angiosarcoma (AS) in Asia: A report from the Asian Sarcoma Consortium (ASC). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00659-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
42
|
Nishikawa T, Yonemori K, Kitano A, Shimoi T, Noguchi E, Yunokawa M, Shimizu C, Fujiwara Y, Yoshida A, Kobayashi E, Nakatani F, Kawai A, Chuman H, Koyama T, Shimomura A, Kitano S, Shimizu T, Fujiwara Y, Yamamoto N, Tamura K. 511P Retrospective study of sarcoma in practical and developmental therapeutics in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw597.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Miura K, Sahara H, Waki S, Kawai A, Sekijima M, Kobayashi T, Zhang Z, Wakai T, Shimizu A, Yamada K. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. Transplant Proc 2016; 48:1315-9. [DOI: 10.1016/j.transproceed.2016.01.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Accepted: 01/28/2016] [Indexed: 12/12/2022]
|
44
|
Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open 2016; 1:e000037. [PMID: 27843593 PMCID: PMC5070259 DOI: 10.1136/esmoopen-2016-000037] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Accepted: 02/02/2016] [Indexed: 01/14/2023] Open
Abstract
Diagnosis and treatment of bone metastasis requires various types of measures, specialists and caregivers. To provide better diagnosis and treatment, a multidisciplinary team approach is required. The members of this multidisciplinary team include doctors of primary cancers, radiologists, pathologists, orthopaedists, radiotherapists, clinical oncologists, palliative caregivers, rehabilitation doctors, dentists, nurses, pharmacists, physical therapists, occupational therapists, medical social workers, etc. Medical evidence was extracted from published articles describing meta-analyses or randomised controlled trials concerning patients with bone metastases mainly from 2003 to 2013, and a guideline was developed according to the Medical Information Network Distribution Service Handbook for Clinical Practice Guideline Development 2014. Multidisciplinary team meetings are helpful in diagnosis and treatment. Clinical benefits such as physical or psychological palliation obtained using the multidisciplinary team approaches are apparent. We established a guideline describing each specialty field, to improve understanding of the different fields among the specialists, who can further provide appropriate treatment, and to improve patients’ outcomes.
Collapse
|
45
|
Kobayashi E, Kawai A, Chuman H. 366P Pazopanib treatment in alveolar soft part sarcomas. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv530.09] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kubota D, Suehara Y, Kobayashi E, Kaneko K, Kawai A, Kondo T. 358O Chemo-responsiveness predictive biomarker discovery for osteosarcoma using microRNA-microarray. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv530.01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Kawai A, Araki N, Ando Y, Nakano K, Machida M, Yoshida P. 3438 Post marketing surveillance (PMS) in Japan for soft tissue sarcoma (STS) patients treated with pazopanib. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31911-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
48
|
Nomura K, Oikawa M, Kawai A, Narumi T, Yasuoka K. GPU-accelerated replica exchange molecular simulation on solid–liquid phase transition study of Lennard-Jones fluids. MOLECULAR SIMULATION 2014. [DOI: 10.1080/08927022.2014.954572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
49
|
Yonemoto T, Takahashi S, Araki N, Sugiura H, Ueda T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T, Matsumine A, Kawai A. Intra- and Inter-Patient Comparison of Efficacy Between Two Phase Ii Studies of Trabectedin (T) in Patients (Pts) with Translocation-Related Sarcomas (Trs); a Randomized Comparative Study (Study-C) and a Single Arm Study (Study-S). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Kubota H, Ogo A, Kawai A, Matsumoto H, Nakamura M, Hirai T. PP069-MON: The Suppressive Effect on Chemotaxis of Eicosapentaenoic Acid on TE-1 Cells. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50404-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|